Clinical Data BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit BioSpaceBridgeBio Pharma plans to file for approval in the third quarter.Rare DiseaseRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) BioSpace BridgeBio Pharma plans to file for approval in the third quarter. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biogen trims Apellis pipeline and R&D team after $5.6bn takeoverNext: Zymeworks cuts deal to buy Theravance for $929m in cash Related Stories Clinical Data GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail pharminent July 17, 2026 Clinical Data AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug pharminent July 15, 2026 Clinical Data AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance pharminent July 15, 2026
